Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 loss |
Therapy | Palbociclib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 loss | Advanced Solid Tumor | no benefit | Palbociclib | Preclinical | Actionable | In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278). | 26649278 |
PubMed Id | Reference Title | Details |
---|---|---|
(26649278) | CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future? | Full reference... |